According to Battle et al., bryostatin-treated chronic lymphocytic leukemia (CLL) cells show induction of protein kinase C and in turn activation of STAT1, which is essential for CLL differentiation. The gene discussed is STAT1; the disease is B-cell chronic lymphocytic leukemia.